AstraZeneca Price to Free Cash Flow Ratio 2010-2023 | AZN

Historical price to free cash flow ratio values for AstraZeneca (AZN) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AstraZeneca Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-05-17 76.90 26.35
2023-12-31 66.33 $2.92 22.73
2023-09-30 66.70 $3.06 21.80
2023-06-30 70.02 $3.03 23.12
2023-03-31 67.91 $2.88 23.55
2022-12-31 65.38 $2.88 22.67
2022-09-30 52.88 $2.60 20.36
2022-06-30 63.26 $2.12 29.90
2022-03-31 63.52 $2.03 31.36
2021-12-31 54.84 $1.71 32.04
2021-09-30 56.54 $1.83 30.95
2021-06-30 55.96 $2.05 27.31
2021-03-31 46.45 $2.17 21.39
2020-12-31 45.81 $1.50 30.50
2020-09-30 50.22 $1.35 37.16
2020-06-30 48.08 $1.08 44.43
2020-03-31 40.60 $0.97 41.80
2019-12-31 44.39 $0.78 56.98
2019-09-30 39.68 $1.12 35.38
2019-06-30 36.38 $0.87 41.65
2019-03-31 35.63 $0.55 64.24
2018-12-31 32.72 $0.63 52.25
2018-09-30 34.09 $0.09 385.23
2018-06-30 29.91 $0.77 39.03
2018-03-31 29.79 $0.86 34.71
2017-12-31 28.76 $0.92 31.18
2017-09-30 28.08 $1.28 21.88
2017-06-30 27.83 $0.72 38.54
2017-03-31 25.42 $0.66 38.70
2016-12-31 21.59 $1.10 19.66
2016-09-30 25.97 $0.58 44.79
2016-06-30 23.54 $0.91 25.74
2016-03-31 21.96 $1.29 17.03
2015-12-31 25.66 $0.81 31.78
2015-09-30 24.05 $1.33 18.10
2015-06-30 23.76 $1.47 16.19
2015-03-31 25.52 $1.92 13.30
2014-12-31 25.53 $2.45 10.40
2014-09-30 25.91 $2.72 9.54
2014-06-30 26.61 $2.44 10.91
2014-03-31 23.23 $2.27 10.25
2013-12-31 20.66 $2.68 7.70
2013-09-30 18.07 $2.87 6.30
2013-06-30 16.17 $2.94 5.49
2013-03-31 17.09 $2.80 6.11
2012-12-31 15.52 $2.56 6.06
2012-09-30 15.71 $2.67 5.88
2012-06-30 14.41 $2.85 5.06
2012-03-31 14.33 $2.67 5.38
2011-12-31 14.29 $2.69 5.31
2011-09-30 13.70 $2.73 5.03
2011-06-30 15.17 $3.07 4.94
2011-03-31 13.97 $3.57 3.92
2010-12-31 13.47 $3.50 3.85
2010-09-30 14.79 $3.76 3.93
2010-06-30 13.56 $3.36 4.04
2010-03-31 12.87 $3.60 3.58
2009-12-31 13.01 $3.75 3.47
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $238.424B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01